Search results for Egfr Inhibitors

Latest updates for Egfr Inhibitors

Fresh curated links around EGFR inhibitors are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

bioengineer.org /1 month ago

26 Years of Advancing EGFR-TKIs in Non-Small Cell Lung Cancer: Breakthroughs in Clinical Use and Resistance Mechanisms

Over the past three decades, the landscape of non-small cell lung cancer (NSCLC) treatment has been profoundly transformed by the advent and continued evolution of epidermal growth...

Read source

bioengineer.org /3 weeks ago

Thioredoxin Reductase 3 Fuels EGFR Inhibitor Resistance

In a groundbreaking study poised to reshape our understanding of therapeutic resistance in aggressive cancers, researchers have unveiled a novel molecular mechanism underlying trea...

Read source

qchron.com /1 week ago

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-...

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third...

Read source

genengnews.com /2 days ago

GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments

Nuvalent’s pipeline is headed by the ROS1 inhibitor zidesamtinib (NVL-520) and the ALK inhibitor eladalkib (NVL-655), which according to the company represent potential best-in-cla...

Read source

journals.plos.org /3 days ago

Retraction: Identification of Potent EGFR Inhibitors from TCM Database@Taiwan

by The PLOS Computational Biology Editors

Read source

fiercebiotech.com /1 month ago

AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with Pinetree Therapeutics.

Read source

biopharmadive.com /1 week ago

Akeso, Summit drug extends survival in closely watched lung cancer trial

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known...

Read source

qchron.com /1 month ago

CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)

SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.